The active enantiomer of T6I-29, T6I-29-1A, was first assessed for its anti-proliferative activities in Y537S ESR1 breast cancer cell lines compared to clinically relevant compounds and other T6I SERMs. This evidence concerns the gene ESR1 and breast cancer.